// App-Quantinova.ai

1850 : Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2

Researchers

Presenter

  • Jeffrey Curtis

Principal Investigators

  • Iain B McInnes

  • Proton Rahman

  • Dafna Gladman

  • Feifei Yang

  • Steve Peterson

  • Alexa Kollmeier

  • Natalie Shiff

  • Chenglong Han

  • May Shawi

  • William Tillett

  • Philip J Mease

Medical Centers

  • Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

  • Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • Memorial University, St. John's, NF, Canada

  • Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada

  • Department of Immunology, Janssen Global Services, LLC, Horsham, PA

  • Janssen Research & Development, San Diego, CA

  • Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Depression

  • Inflammatory Arthritis

  • Anxiety

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved